Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Inventory (2016 - 2025)

Ligand Pharmaceuticals' Inventory history spans 15 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Inventory fell 35.34% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 35.34%, while the annual FY2025 figure was $9.1 million, 35.34% down from the prior year.
  • Inventory for Q4 2025 was $9.1 million at Ligand Pharmaceuticals, down from $11.9 million in the prior quarter.
  • Across five years, Inventory topped out at $39.9 million in Q2 2021 and bottomed at $9.1 million in Q4 2025.
  • The 5-year median for Inventory is $22.3 million (2022), against an average of $22.0 million.
  • The largest annual shift saw Inventory soared 979.04% in 2021 before it plummeted 51.35% in 2022.
  • A 5-year view of Inventory shows it stood at $27.3 million in 2021, then tumbled by 51.35% to $13.3 million in 2022, then skyrocketed by 80.3% to $24.0 million in 2023, then tumbled by 41.12% to $14.1 million in 2024, then tumbled by 35.34% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Inventory are $9.1 million (Q4 2025), $11.9 million (Q3 2025), and $15.5 million (Q2 2025).